Samuel McNeely

1.4k total citations
33 papers, 928 citations indexed

About

Samuel McNeely is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Samuel McNeely has authored 33 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel McNeely's work include DNA Repair Mechanisms (8 papers), Cancer-related Molecular Pathways (7 papers) and Retinoids in leukemia and cellular processes (6 papers). Samuel McNeely is often cited by papers focused on DNA Repair Mechanisms (8 papers), Cancer-related Molecular Pathways (7 papers) and Retinoids in leukemia and cellular processes (6 papers). Samuel McNeely collaborates with scholars based in United States, France and United Kingdom. Samuel McNeely's co-authors include Richard P. Beckmann, J. Christopher States, Aimee Bence Lin, Michael J. McCabe, Darlene Barnard, Wayne Blosser, Heather Lee Miller, Jack Dempsey, Mark S. Marshall and Constance King and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Clinical Nutrition.

In The Last Decade

Samuel McNeely

32 papers receiving 907 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel McNeely United States 18 621 379 116 110 109 33 928
In‐Chul Park South Korea 19 664 1.1× 178 0.5× 45 0.4× 191 1.7× 92 0.8× 30 926
Anja J. Stauber United States 12 612 1.0× 375 1.0× 27 0.2× 207 1.9× 80 0.7× 13 1.0k
Boshi Sun China 13 349 0.6× 138 0.4× 106 0.9× 152 1.4× 61 0.6× 24 674
Dakai Xiao China 18 711 1.1× 499 1.3× 49 0.4× 218 2.0× 256 2.3× 29 1.2k
Uma Giri United States 23 984 1.6× 472 1.2× 82 0.7× 489 4.4× 263 2.4× 51 1.6k
Haiping Pei China 19 279 0.4× 300 0.8× 90 0.8× 130 1.2× 104 1.0× 38 730
Qian Ma China 14 373 0.6× 129 0.3× 30 0.3× 179 1.6× 59 0.5× 35 611
Yongdong Niu China 16 414 0.7× 222 0.6× 125 1.1× 159 1.4× 93 0.9× 43 890
Kayoko Kita Japan 12 1.5k 2.4× 221 0.6× 62 0.5× 1.3k 12.0× 70 0.6× 20 2.1k

Countries citing papers authored by Samuel McNeely

Since Specialization
Citations

This map shows the geographic impact of Samuel McNeely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel McNeely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel McNeely more than expected).

Fields of papers citing papers by Samuel McNeely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel McNeely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel McNeely. The network helps show where Samuel McNeely may publish in the future.

Co-authorship network of co-authors of Samuel McNeely

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel McNeely. A scholar is included among the top collaborators of Samuel McNeely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel McNeely. Samuel McNeely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hollebecque, Antoine, Takafumi Koyama, Yutaka Fujiwara, et al.. (2025). Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.. Journal of Clinical Oncology. 43(16_suppl). 3507–3507.
2.
Roeker, Lindsey E., Jennifer A. Woyach, Chan Y. Cheah, et al.. (2024). Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 144(13). 1374–1386. 11 indexed citations
3.
Konstantinopoulos, Panagiotis A., Jungmin Lee, Bo Gao, et al.. (2022). A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecologic Oncology. 167(2). 213–225. 42 indexed citations
4.
Byers, Lauren A., Alejandro Navarro, Eric Schaefer, et al.. (2021). A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer. 22(6). 531–540. 27 indexed citations
5.
Chau, Ian, Nicolas Penel, Andres O. Soriano, et al.. (2020). Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers. 12(10). 2985–2985. 22 indexed citations
6.
Herbst, Roy S., Hendrik‐Tobias Arkenau, Emiliano Calvo, et al.. (2020). Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. Journal of Clinical Oncology. 38(15_suppl). 3089–3089. 3 indexed citations
7.
Saleh, Mansoor N., Philippe A. Cassier, Lauriane Eberst, et al.. (2019). Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study. Annals of Oncology. 30. iv124–iv124. 1 indexed citations
8.
9.
King, Constance, Samuel McNeely, Darlene Barnard, et al.. (2015). LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Molecular Cancer Therapeutics. 14(9). 2004–2013. 139 indexed citations
10.
McNeely, Samuel, et al.. (2013). CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacology & Therapeutics. 142(1). 1–10. 131 indexed citations
11.
Landau, Heather, Samuel McNeely, Jayasree S. Nair, et al.. (2012). The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53 -Mutated Multiple Myeloma Cells. Molecular Cancer Therapeutics. 11(8). 1781–1788. 48 indexed citations
12.
McNeely, Samuel, Chiara Conti, Tahir Sheikh, et al.. (2010). Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle. 9(5). 995–1004. 68 indexed citations
13.
Salazar, Ana María, Heather Lee Miller, Samuel McNeely, et al.. (2009). Suppression of p53 and p21CIP1/WAF1Reduces Arsenite-Induced Aneuploidy. Chemical Research in Toxicology. 23(2). 357–364. 12 indexed citations
14.
McNeely, Samuel, et al.. (2008). Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent. Toxicology and Applied Pharmacology. 231(1). 61–67. 32 indexed citations
15.
McNeely, Samuel, et al.. (2008). Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization. Toxicology and Applied Pharmacology. 230(2). 235–246. 27 indexed citations
16.
McNeely, Samuel, et al.. (2008). Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. Toxicology and Applied Pharmacology. 229(2). 252–261. 31 indexed citations
17.
McNeely, Samuel, et al.. (2006). Exit from Arsenite-Induced Mitotic Arrest Is p53 Dependent. Environmental Health Perspectives. 114(9). 1401–1406. 17 indexed citations
18.
McNeely, Samuel, et al.. (2006). p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1. Journal of Pharmacology and Experimental Therapeutics. 318(1). 142–151. 42 indexed citations
19.
States, J. Christopher, John J. Reiners, Joel G. Pounds, et al.. (2002). Arsenite Disrupts Mitosis and Induces Apoptosis in SV40-Transformed Human Skin Fibroblasts. Toxicology and Applied Pharmacology. 180(2). 83–91. 43 indexed citations
20.
Stein, E A, Samuel McNeely, & P M Steiner. (1979). Electrophoretic separation of high-density lipoprotein choelsterol evaluated and compared with the modified lipid research clinic procedure.. Clinical Chemistry. 25(11). 1934–1938. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by In‐Chul Park Breakdown of academic impact, for papers by Anja J. Stauber Breakdown of academic impact, for papers by Boshi Sun Breakdown of academic impact, for papers by Dakai Xiao Breakdown of academic impact, for papers by Uma Giri Breakdown of academic impact, for papers by Haiping Pei Breakdown of academic impact, for papers by Qian Ma Breakdown of academic impact, for papers by Yongdong Niu Breakdown of academic impact, for papers by Kayoko Kita
Rankless by CCL
2026